gene

CLDN5

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about CLDN5: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

398Connections

3Hypotheses

3Analyses

50Outgoing

50Incoming

0Experiments

4Debates

Summary

CLDN5 is a gene implicated in neurodegeneration research. Key relationships include: activates, inhibits, co discussed. Associated with ALS, Als, Brain Arteriovenous Malformations. Connected to 121 entities in the SciDEX knowledge graph.

View on Wiki →

No AI portrait yet

🧬 Gene Info

Gene Symbol	CLDN5
Full Name	Claudin-5
Chromosome	22q11.21.
Protein Type	Structural Protein
Target Class	Structural Protein
Function	Tight junction protein modulation - no established druggable mechanisms
Mechanism of Action	Tight junction protein modulation - no established druggable mechanisms
Primary Expression	Brain endothelial cells, Tight junctions of blood-brain barrier
Druggability	Undruggable (0.20)
Clinical Stage	Approved
Amino Acids	218 aa
Exons	4
Pathways	Cerebrovascular
UniProt ID	O00511
NCBI Gene ID	9079
Ensembl ID	ENSG00000184113
OMIM	602507
GeneCards	CLDN5
Human Protein Atlas	CLDN5
Associated Diseases	ALS, blood-retinal barrier integrity, Brain Edema, neurodegeneration, stroke
Known Drugs/Compounds	curcumin, resveratrol
Interactions	ABCB1, ABCD1, ABCD2, ABCG2, AMYLOID, AND
SciDEX Target	View Target Profile (5 clinical trials)
SciDEX Hypotheses	Vascular-Glial Interface Restoration Vascular and Perivascular Cell Type Vulnerability: HBOT at 1.5 ATA for 90 days restores BBB integrity
KG Connections	398 knowledge graph edges
Databases	GeneCards HPA STRING

🔮 Predicted Structure: CLDN5 — AlphaFold O00511 Click to expand

AI-predicted structure from AlphaFold | Powered by Mol*

Wiki Pages (1)

Knowledge base pages for this entity

Canonical Page

CLDN5 — Claudin-5

gene · 699 words

→

Pathway Diagram

graph TD
    CLDN5["CLDN5"]
    CLDN5 -->|"encodes"| CLAUDIN5["CLAUDIN5"]
    CLDN5 -->|"encodes"| Claudin_5["Claudin-5"]
    CLDN5 -->|"activates"| Stroke["Stroke"]
    CLDN5 -->|"inhibits"| Als["Als"]
    CLDN5 -->|"target for"| Ms["Ms"]
    CLDN5 -->|"inhibits"| ALS["ALS"]
    h_7a8d7379["h-7a8d7379"] -->|"target for"| CLDN5
    H3K27me3["H3K27me3"] -->|"inhibits"| CLDN5
    AUTOPHAGY["AUTOPHAGY"] -->|"regulates"| CLDN5
    OCLN["OCLN"] -->|"activates"| CLDN5
    BECN1["BECN1"] -->|"activates"| CLDN5
    CXCL2["CXCL2"] -->|"inhibits"| CLDN5
    IL6["IL6"] -->|"inhibits"| CLDN5
    ATF4["ATF4"] -->|"target for"| CLDN5
    PPP1R15A["PPP1R15A"] -->|"target for"| CLDN5

Outgoing (264)

Target	Relation	Type	Str
ds-f2c28aed24a7	provides_data_for	dataset	1.00
Blood-Brain Barrier Integrity	component_of	phenotype	0.95
Blood-Brain Barrier Integrity	regulates	phenotype	0.95
BLOOD-BRAIN BARRIER	involved_in	entity	0.95
Blood-Retinal Barrier Integrity	promotes	phenotype	0.95
Blood-Brain Barrier	involved_in	process	0.95
TIGHT JUNCTION	involved_in	entity	0.95
BBB	regulates	process	0.90
blood-retinal barrier integrity	associated_with	phenotype	0.90
Brain Arteriovenous Malformations	biomarker_for	disease	0.90
Blood-Brain Barrier Integrity	involved_in	phenotype	0.90
MICROGLIA	expressed_in	entity	0.85
Tight Junctions	involved_in	process	0.85
Blood-Brain Barrier Disruption	involved_in	process	0.85
Brain Edema	associated_with	phenotype	0.85
Glioma Progression	downregulates	process	0.85
Cerebrovascular Disease	therapeutic_target	disease	0.83
Brain Arteriovenous Malformations	downregulates	disease	0.80
Stroke	biomarker_for	disease	0.80
Cerebral Cortex	expressed_in	brain_region	0.80
Glioma	downregulates	disease	0.80
Blood-Brain Barrier Disruption	biomarker_for	phenotype	0.80
blood-brain barrier integrity	mediates	phenotype	0.80
CLAUDIN5	encodes	protein	0.80
claudin_5	encodes	protein	0.80
Glioblastoma	biomarker_for	disease	0.75
OCLN	expresses	gene	0.70
ENDOTHELIAL	protects_against	cell_type	0.70
Glioblastoma Multiforme	suppresses	disease	0.70
OCLN	co_mentioned_with	gene	0.70
neurons	expressed_in	cell_type	0.70
DRP1	protects_against	gene	0.70
DRP1	inhibits	gene	0.70
neurons	promotes	cell_type	0.70
Claudin-5	encodes	protein	0.70
blood_brain_barrier	maintains	structure	0.70
Blood-Brain Barrier	activates	pathway	0.70
Stroke	activates	disease	0.65
Als	inhibits	disease	0.65
Dementia	therapeutic_target	disease	0.65
Depression	activates	disease	0.65
Inflammation	activates	disease	0.65
Als	therapeutic_target	disease	0.65
Ms	therapeutic_target	disease	0.65
Carcinoma	inhibits	disease	0.65
Inflammation	interacts_with	disease	0.65
Vascular Dementia	interacts_with	disease	0.65
Dementia	interacts_with	disease	0.65
STROKE	accumulates_in	disease	0.65
ALS	inhibits	disease	0.65

Incoming (134)

Source	Relation	Type	Str
ds-f2c28aed24a7	data_in	dataset	1.00
TJP1	interacts_with_confidence_0.993	gene	0.99
OCLN	interacts_with_confidence_0.99	gene	0.99
Brain Arteriovenous Malformations	downregulates	disease	0.95
DTG	downregulates	entity	0.95
BRAIN ARTERIOVENOUS MALFORMATIONS	downregulates	entity	0.95
Autophagy	regulates	process	0.95
Brain Microvascular Endothelial Cells	expressed_in	cell_type	0.92
Drp1 Inhibition	upregulates	mechanism	0.90
CAV1	mediates	protein	0.90
ER STRESS	downregulates	entity	0.90
h-7a8d7379	targets_gene	hypothesis	0.90
RUPTURED BRAIN ARTERIOVENOUS MALFORMATIONS	downregulates	entity	0.90
CAV1	regulates	gene	0.85
Hypoxia	causes	process	0.85
Autophagy	degrades	process	0.85
DRP1 inhibition	upregulates	drug	0.85
Cavernomas	associated_with	disease	0.85
Endoplasmic Reticulum Stress	downregulates	process	0.80
h-7a8d7379	targets	hypothesis	0.80
CAVERNOMAS	associated_with	entity	0.80
LICOCUMARONE	stabilizes	drug	0.80
autophagy	degrades	process	0.80
LC3	mediates	entity	0.75
H3K27me3	inhibits	process	0.70
AUTOPHAGY	regulates	pathway	0.64
ABCG2	activates	gene	0.60
IL12B	inhibits	gene	0.60
XBP1	therapeutic_target	gene	0.60
CXCL1	inhibits	gene	0.60
DDIT3	therapeutic_target	gene	0.60
HSPA5	therapeutic_target	gene	0.60
PERK	therapeutic_target	gene	0.60
IRE1	therapeutic_target	gene	0.60
ANGPT1	inhibits	gene	0.60
ACTB	regulates	gene	0.60
APOE	targets	gene	0.60
ANGPT1	associated_with	gene	0.60
APOE	binds_to	gene	0.60
ABCB1	activates	gene	0.60
ABCB1	inhibits	gene	0.60
CDH5	associated_with	gene	0.60
ROS	activates	gene	0.60
STROKE	activates	gene	0.60
BLOOD-BRAIN BARRIER DYSFUNCTION	activates	gene	0.60
GENES	regulates	gene	0.60
GENES	inhibits	gene	0.60
OCLN	activates	gene	0.60
BECN1	activates	gene	0.60
CXCL2	inhibits	gene	0.60

Targeting Hypotheses (3)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
Vascular-Glial Interface Restoration	0.716	neurodegeneration	Cell type vulnerability in Alzheimers Di
Vascular and Perivascular Cell Type Vulnerability: BBB Integ	0.470	neurodegeneration	Cell type vulnerability debate in Alzhei
HBOT at 1.5 ATA for 90 days restores BBB integrity by upregu	0.460	neurodegeneration	What are the optimal oxygen pressure, du

Mentioning Analyses (3)

Scientific analyses that reference this entity

Experiments (0)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
No experiments found

Related Papers (0)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
No papers found

Debates (4)

Multi-agent debates referencing this entity